Technical brief |

Barriers to Access and Scale-Up of Hepatitis C Treatment: Spotlight on Daclatasvir

The international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) began introducing hepatitis C virus (HCV) treatment to several patients in India in 2013. MSF is in the process of scaling up treatment for HCV in at least eight additional countries, using direct-acting antiviral (DAA) medicines that have recently come to market with the potential to revolutionise treatment for people living with HCV.

Given the significant potential to improve HCV treatment using the drug daclatasvir, developed by Bristol- Myers Squibb (BMS), MSF puts forth its concerns, comments and recommendations to make daclatasvir available and affordable in developing countries.